Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The current study will allow the assessment of pharmacokinetics, pharmacodynamics,
elimination rate and clearance of dabigatran etexilate during and following haemodialysis in
ESRD patients.